Hikal Limited Q3FY21 Record breaking performance backed by strong product portfolio and strategic geographic expansion

04 Feb 2021

• Revenue of Rs. 463 crores; YoY growth of 15%
• EBITDA of Rs. 91 crores; YoY growth of 21%
• EBITDA Margin of 19.7%; Expansion of 99 bps
• PAT of Rs. 40 crores; YoY growth of 42%
• Interim Dividend of Rs.1.00 per share (50 % of Face Value of Rs. 2 per share)

• Better sales volumes of new and existing products as well as penetration in new markets led to record breaking performance.
• Steady improvement in EBITDA Margins continues aided by products portfolio as well as geographic expansion.
• Pharmaceutical sales up by 8% to Rs. 269 croresas compared to Rs. 248 croresin the corresponding period of the previous year
  1. Continued customer demand provides a positive outlook on the business.
  2. Strong pipeline of new products in Contract Manufacturing and Generics
  3. Business excellence initiatives yielding better utilization of production capacities.

• Crop Protection sales up by 25% at Rs. 194 crores as compared to Rs. 156 crores in the corresponding period of the previous year
  1. Strong pipeline of inquiries and new products under commercialization
  2. Business excellence initiatives driving better throughput

Commenting on the results, Jai Hiremath, Chairman & Managing Director, Hikal Ltd. said,
“I am pleased to report that we have achieved the highest ever quarterly revenue and net profit as a company. After facing several challenges through the pandemic both our businesses are now back on track.